Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Amy

Paller

,

MS, MD

Walter J. Hamlin Professor and Chair
Northwestern University Feinberg Medical School
Chicago
,
Illinois
,
United States
Councilor Since: March 1, 2010
IPC Board Member
Request an Update
Dr. Amy Paller is the Walter J. Hamlin Professor and Chair of Dermatology, Professor of Pediatrics, and Principal Investigator of the NIH-funded Skin Biology and Diseases Resource-based Center at Northwestern University’s Feinberg School of Medicine. She received her undergraduate and graduate degrees from Brown University and her medical degree from Stanford University. Dr. Paller completed residency training in Pediatrics and Dermatology at Northwestern University and her postdoctoral research fellowship at the University of North Carolina. An author of >750 original publications, Dr. Paller is an NIH-funded investigator conducting laboratory-based and clinical investigations related to psoriasis. Dr. Paller has led international epidemiological studies on psoriasis and atopic dermatitis, developed new tools to measure patient-related outcomes in pediatric inflammatory skin disease, and focused on psoriasis research on obesity, cutaneous innervation, and new nanotechnology-based treatment approaches. She has been the lead investigator on landmark trials in pediatric skin disease, including the first TNF inhibitor and the first IL-17 inhibitor for children with psoriasis, as well as several new topical and systemic therapies for atopic dermatitis. She has served on the Medical Advisory Board (now Emeritus) and received the Excellence in Leadership Award from the National Psoriasis Foundation (NPF). Dr. Paller has been an active IPC Councilor since 2010 and is now a member of IPC’s Board of Directors. She has served as Chair of the National Eczema Association’s Scientific and Medical Advisory Council and was co-founder and inaugural President of the International Eczema Council (IEC). She has also been President of the Society for Investigative Dermatology (SID), the Society for Pediatric Dermatology (SPD), the Pediatric Dermatology Research Alliance (PeDRA), the Women’s Dermatological Society (WDS), the International Society of Pediatric Dermatology (ISPD), and the American Dermatological Association (ADA). She has served on the Board of many national and international organizations, including the American Academy of Dermatology (AAD) and the American Board of Dermatology (ABD), and on the editorial boards of leading journals, including, currently, as Section Editor of the Journal of Investigative Dermatology (JID). She has written several textbooks, including the leading textbook for pediatric dermatology, Hurwitz Clinical Pediatric Dermatology.
Last Updated:
02/19/2026

Areas of Interest

Bench Research, Nanoconstruct Gene-Regulatory Treatments for Psoriasis, Neuroimmunology and Keratinocyte Cross-Talk in Psoriasis, Obesity-Related Impacts on Psoriasis Severity and Treatment Response, Epidemiologic Studies, Clinical Trials, Patient-Reported Outcomes Research, Pediatric Itch Assessment Tools, PROMIS Itch Questionnaire–Childhood, Stigma Measurement Tools, Pediatric Dermatology

IPC Committees / Groups

Board Member, Pediatric Global Burden Task Force, Pediatric Psoriasis Working Group

Languages Spoken

English

Involvement with Other Organization(s)

Dr. Paller participates in the National Psoriasis Foundation’s (NPF) activities and was previously an NPF medical Board Member.
Recent publications

Featured

Video

Anti-TNF-a Induced Skin Eruptions in Patients with IBD: Presentation & Clinical Approach in Children.

Dr. Amy Paller presents on the clinical presentation and management of anti-TNF-α–induced cutaneous eruptions in…

Watch Video

PDF

A Report from the 2026 American Academy of Dermatology (AAD) Annual Meeting.

What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis…

View Report

PDF

The Global Burden of Pediatric Psoriasis: A Systematic Review.

View Report

PDF

IPC Psoriasis Disease Severity Reclassification: Update on Validity, Acceptance, and Implementation.

View Report

Video

Psoriasis Look-Alikes: TNF Inhibitor-Induced Psoriasiform Dermatitis.

IPC Board Member Dr. Amy Paller highlights the under-recognition of psoriasis in children and pediatric patients. She…

Watch Video

PDF

Investigation of the Applicability of Adult Definitions of Disease Severity for Psoriasis in a Pediatric Cohort: A…

Conflicts of interest Dr Al-Gawahiri carried out clinical trials for Janssen. All funding is not personal but goes to…

View Report

Video

EADV Part III Panel Discussion: Challenging Clinical Cases.

Dr. Satveer Mahil leads a panel of global psoriasis experts as they answer questions from the second and third parts of…

Watch Video

Video

Recent Treatment Advances in Pediatric Psoriasis.

Dr. Amy Paller highlights recent treatment developments in pediatric psoriasis, emphasizing this group's high rate of…

Watch Video

Blog

Focus on Psoriasis: A Report from the 33rd Annual European Academy of Dermatology and Venereology (EADV) Congress.

The 33rd Annual EADV Congress in Amsterdam featured updates on psoriasis care, including highlights from the IPC…

Read More

Blog

Getting to Know IPC's Board Member Amy Paller: What Inspired Me to Specialize in Psoriasis.

Meet Dr. Amy Paller, a leading pediatric dermatologist and researcher from Chicago, Illinois, and a Board Member of the…

Read More

Event

Symposium: Data Driven Care in Psoriasis.

EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY (EADV) | AMSTERDAM, NETHERLANDS Program chairs: Lone Skov, Denmark and…

September 25, 2024
Learn More or Register

Blog

IPC Elects Two New Board Members.

Discover the latest additions to the IPC’s Board of Directors, key psoriasis leaders, André Carvalho and Amy Paller.…

Read More

PDF

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.

View Report

PDF

Association of Pediatric Psoriasis Severity With Excess and Central Adiposity.

View Report

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026